Bupropion: A review of its mechanism of antidepressant activity

J. A. Ascher, J. O. Cole, J. N. Colin, J. P. Feighner, R. M. Ferris, H. C. Fibiger, R. N. Golden, P. Martin, W. Z. Potter, E. Richelson, F. Sulser

Research output: Contribution to journalArticle

635 Citations (Scopus)

Abstract

Background: The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of the relevant biochemical, in vivo brain microdialysis, electrophysiologic, behavioral, and clinical data clarifies what is known about this unique compound and suggests possible modes of action. Method: A panel of 11 experts was convened for a conference to discuss bupropion's mechanism of antidepressant activity. Four of the panelists presented current research findings, followed by a discussion. Results: (1) Biochemical studies suggest down-regulation of postsynaptic β-adrenoceptors and desensitization of the norepinephrine- stimulated adenylate cyclase in the rat cortex occur only after chronic administration of very high doses of bupropion. (2) In vivo brain microdialysis studies demonstrate that, after chronic administration, there is an enhancement of bupropion-induced increases in extracellular dopamine in the nucleus accumbens. (3) Electrophysiologic data show that with acute dosing, bupropion reduces the firing rates of noradrenergic neurons in the locus ceruleus. The firing rates of dopaminergic neurons are reduced by bupropion in the A9 and A10 areas of the brain, but only at very high doses, and bupropion does not alter the firing rates of serotonergic neurons in the dorsal raphe. (4) Behavioral studies show that the most active metabolite of bupropion, hydroxybupropion (306U73), appears to be responsible for a large part of the compound's effects in animal models of antidepressant activity. (5) Clinical studies indicate that bupropion enhances noradrenergic functional activity as reflected by an increased excretion of the hydroxy metabolite of melatonin, while at the same time producing a presumably compensatory decrease in norepinephrine turnover. In one study, bupropion elevated plasma levels of the dopamine metabolite homovanillic acid in nonresponders, but not in responders. Conclusion: The mechanism of action of bupropion appears to have an unusual, not fully understood, noradrenergic link. The bupropion metabolite hydroxybupropion probably plays a critical role in bupropion's antidepressant activity, which appears to be predominantly associated with long-term noradrenergic effects. The mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. There is some evidence that dopamine may contribute to bupropion's antidepressant properties. Antidepressant effects of bupropion are not serotonergically mediated.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalJournal of Clinical Psychiatry
Volume56
Issue number7 SUPPL.
StatePublished - 1995
Externally publishedYes

Fingerprint

Bupropion
Antidepressive Agents
Dopamine
Microdialysis
Norepinephrine
Brain
Serotonergic Neurons
Adrenergic Neurons
Homovanillic Acid
Locus Coeruleus
Dopaminergic Neurons
antineoplaston A10
Nucleus Accumbens
Melatonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., ... Sulser, F. (1995). Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56(7 SUPPL.), 395-401.

Bupropion : A review of its mechanism of antidepressant activity. / Ascher, J. A.; Cole, J. O.; Colin, J. N.; Feighner, J. P.; Ferris, R. M.; Fibiger, H. C.; Golden, R. N.; Martin, P.; Potter, W. Z.; Richelson, E.; Sulser, F.

In: Journal of Clinical Psychiatry, Vol. 56, No. 7 SUPPL., 1995, p. 395-401.

Research output: Contribution to journalArticle

Ascher, JA, Cole, JO, Colin, JN, Feighner, JP, Ferris, RM, Fibiger, HC, Golden, RN, Martin, P, Potter, WZ, Richelson, E & Sulser, F 1995, 'Bupropion: A review of its mechanism of antidepressant activity', Journal of Clinical Psychiatry, vol. 56, no. 7 SUPPL., pp. 395-401.
Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al. Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry. 1995;56(7 SUPPL.):395-401.
Ascher, J. A. ; Cole, J. O. ; Colin, J. N. ; Feighner, J. P. ; Ferris, R. M. ; Fibiger, H. C. ; Golden, R. N. ; Martin, P. ; Potter, W. Z. ; Richelson, E. ; Sulser, F. / Bupropion : A review of its mechanism of antidepressant activity. In: Journal of Clinical Psychiatry. 1995 ; Vol. 56, No. 7 SUPPL. pp. 395-401.
@article{35c7c78cda8743aba9279972c377283d,
title = "Bupropion: A review of its mechanism of antidepressant activity",
abstract = "Background: The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of the relevant biochemical, in vivo brain microdialysis, electrophysiologic, behavioral, and clinical data clarifies what is known about this unique compound and suggests possible modes of action. Method: A panel of 11 experts was convened for a conference to discuss bupropion's mechanism of antidepressant activity. Four of the panelists presented current research findings, followed by a discussion. Results: (1) Biochemical studies suggest down-regulation of postsynaptic β-adrenoceptors and desensitization of the norepinephrine- stimulated adenylate cyclase in the rat cortex occur only after chronic administration of very high doses of bupropion. (2) In vivo brain microdialysis studies demonstrate that, after chronic administration, there is an enhancement of bupropion-induced increases in extracellular dopamine in the nucleus accumbens. (3) Electrophysiologic data show that with acute dosing, bupropion reduces the firing rates of noradrenergic neurons in the locus ceruleus. The firing rates of dopaminergic neurons are reduced by bupropion in the A9 and A10 areas of the brain, but only at very high doses, and bupropion does not alter the firing rates of serotonergic neurons in the dorsal raphe. (4) Behavioral studies show that the most active metabolite of bupropion, hydroxybupropion (306U73), appears to be responsible for a large part of the compound's effects in animal models of antidepressant activity. (5) Clinical studies indicate that bupropion enhances noradrenergic functional activity as reflected by an increased excretion of the hydroxy metabolite of melatonin, while at the same time producing a presumably compensatory decrease in norepinephrine turnover. In one study, bupropion elevated plasma levels of the dopamine metabolite homovanillic acid in nonresponders, but not in responders. Conclusion: The mechanism of action of bupropion appears to have an unusual, not fully understood, noradrenergic link. The bupropion metabolite hydroxybupropion probably plays a critical role in bupropion's antidepressant activity, which appears to be predominantly associated with long-term noradrenergic effects. The mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. There is some evidence that dopamine may contribute to bupropion's antidepressant properties. Antidepressant effects of bupropion are not serotonergically mediated.",
author = "Ascher, {J. A.} and Cole, {J. O.} and Colin, {J. N.} and Feighner, {J. P.} and Ferris, {R. M.} and Fibiger, {H. C.} and Golden, {R. N.} and P. Martin and Potter, {W. Z.} and E. Richelson and F. Sulser",
year = "1995",
language = "English (US)",
volume = "56",
pages = "395--401",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Bupropion

T2 - A review of its mechanism of antidepressant activity

AU - Ascher, J. A.

AU - Cole, J. O.

AU - Colin, J. N.

AU - Feighner, J. P.

AU - Ferris, R. M.

AU - Fibiger, H. C.

AU - Golden, R. N.

AU - Martin, P.

AU - Potter, W. Z.

AU - Richelson, E.

AU - Sulser, F.

PY - 1995

Y1 - 1995

N2 - Background: The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of the relevant biochemical, in vivo brain microdialysis, electrophysiologic, behavioral, and clinical data clarifies what is known about this unique compound and suggests possible modes of action. Method: A panel of 11 experts was convened for a conference to discuss bupropion's mechanism of antidepressant activity. Four of the panelists presented current research findings, followed by a discussion. Results: (1) Biochemical studies suggest down-regulation of postsynaptic β-adrenoceptors and desensitization of the norepinephrine- stimulated adenylate cyclase in the rat cortex occur only after chronic administration of very high doses of bupropion. (2) In vivo brain microdialysis studies demonstrate that, after chronic administration, there is an enhancement of bupropion-induced increases in extracellular dopamine in the nucleus accumbens. (3) Electrophysiologic data show that with acute dosing, bupropion reduces the firing rates of noradrenergic neurons in the locus ceruleus. The firing rates of dopaminergic neurons are reduced by bupropion in the A9 and A10 areas of the brain, but only at very high doses, and bupropion does not alter the firing rates of serotonergic neurons in the dorsal raphe. (4) Behavioral studies show that the most active metabolite of bupropion, hydroxybupropion (306U73), appears to be responsible for a large part of the compound's effects in animal models of antidepressant activity. (5) Clinical studies indicate that bupropion enhances noradrenergic functional activity as reflected by an increased excretion of the hydroxy metabolite of melatonin, while at the same time producing a presumably compensatory decrease in norepinephrine turnover. In one study, bupropion elevated plasma levels of the dopamine metabolite homovanillic acid in nonresponders, but not in responders. Conclusion: The mechanism of action of bupropion appears to have an unusual, not fully understood, noradrenergic link. The bupropion metabolite hydroxybupropion probably plays a critical role in bupropion's antidepressant activity, which appears to be predominantly associated with long-term noradrenergic effects. The mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. There is some evidence that dopamine may contribute to bupropion's antidepressant properties. Antidepressant effects of bupropion are not serotonergically mediated.

AB - Background: The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of the relevant biochemical, in vivo brain microdialysis, electrophysiologic, behavioral, and clinical data clarifies what is known about this unique compound and suggests possible modes of action. Method: A panel of 11 experts was convened for a conference to discuss bupropion's mechanism of antidepressant activity. Four of the panelists presented current research findings, followed by a discussion. Results: (1) Biochemical studies suggest down-regulation of postsynaptic β-adrenoceptors and desensitization of the norepinephrine- stimulated adenylate cyclase in the rat cortex occur only after chronic administration of very high doses of bupropion. (2) In vivo brain microdialysis studies demonstrate that, after chronic administration, there is an enhancement of bupropion-induced increases in extracellular dopamine in the nucleus accumbens. (3) Electrophysiologic data show that with acute dosing, bupropion reduces the firing rates of noradrenergic neurons in the locus ceruleus. The firing rates of dopaminergic neurons are reduced by bupropion in the A9 and A10 areas of the brain, but only at very high doses, and bupropion does not alter the firing rates of serotonergic neurons in the dorsal raphe. (4) Behavioral studies show that the most active metabolite of bupropion, hydroxybupropion (306U73), appears to be responsible for a large part of the compound's effects in animal models of antidepressant activity. (5) Clinical studies indicate that bupropion enhances noradrenergic functional activity as reflected by an increased excretion of the hydroxy metabolite of melatonin, while at the same time producing a presumably compensatory decrease in norepinephrine turnover. In one study, bupropion elevated plasma levels of the dopamine metabolite homovanillic acid in nonresponders, but not in responders. Conclusion: The mechanism of action of bupropion appears to have an unusual, not fully understood, noradrenergic link. The bupropion metabolite hydroxybupropion probably plays a critical role in bupropion's antidepressant activity, which appears to be predominantly associated with long-term noradrenergic effects. The mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. There is some evidence that dopamine may contribute to bupropion's antidepressant properties. Antidepressant effects of bupropion are not serotonergically mediated.

UR - http://www.scopus.com/inward/record.url?scp=0028787766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028787766&partnerID=8YFLogxK

M3 - Article

C2 - 7665537

AN - SCOPUS:0028787766

VL - 56

SP - 395

EP - 401

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7 SUPPL.

ER -